Circulation Research, Vol 74, 1121-1125, Copyright © 1994 by American Heart Association

ARTICLES

Methylene blue reverses endotoxin-induced hypotension

JF Keaney Jr, JC Puyana, S Francis, JF Loscalzo, JS Stamler and J Loscalzo
Department of Medicine, Brigham and Women's Hospital, Boston, Mass.

Hypotension in septic shock is a reflection of unregulated nitric oxide (NO) production and vascular smooth muscle guanylyl cyclase activation. We examined the effect of methylene blue on lipopolysaccharide (LPS)- induced shock in anesthetized rabbits. Shock was induced with 150 micrograms/kg LPS after measurement of mean arterial pressure, platelet cGMP, and total plasma NO (nitrogen monoxide+S-nitrosothiol) content. Measurements were repeated before and after the intravenous administration of 1, 5, and 10 mg/kg methylene blue in response to a 55% reduction in mean arterial pressure. At baseline, mean +/- SEM arterial pressure was 88 +/- 3 mm Hg, which fell to 51 +/- 3 mm Hg after LPS (P < .05). Methylene blue at doses of 1, 5, and 10 mg/kg produced a prompt dose-dependent increase in mean arterial pressure to 69 +/- 2, 77 +/- 3, and 81 +/- 2 mm Hg, respectively (P < .05 versus mean arterial pressure after LPS) in association with normalization of plasma total NO content (P < .05); however, methylene blue did not significantly affect intraplatelet cGMP levels. Thus, methylene blue restores normal arterial pressure in rabbits with septic shock. This effect is associated with persistent elevation of intraplatelet cGMP levels and normalization of total plasma NO content. These data are consistent with methylene blue-mediated inhibition of NO synthase and/or degradation of NO in this model and suggest a novel therapeutic approach to the treatment of septic shock.

This article has been cited by other articles:

				D. Fernandes, R. Sordi, L. K. Pacheco, G. M. Nardi, B. T. Heckert, C. G. Villela, A. R. Lobo, C. Barja-Fidalgo, and J. Assreuy Late, but Not Early, Inhibition of Soluble Guanylate Cyclase Decreases Mortality in a Rat Sepsis Model J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 991 - 999. [Abstract] [Full Text] [PDF]

				D. Fernandes, J. E. da Silva-Santos, D. Duma, C. G. Villela, C. Barja-Fidalgo, and J. Assreuy Nitric Oxide-Dependent Reduction in Soluble Guanylate Cyclase Functionality Accounts for Early Lipopolysaccharide-Induced Changes in Vascular Reactivity Mol. Pharmacol., March 1, 2006; 69(3): 983 - 990. [Abstract] [Full Text] [PDF]

				F. van Bel, V. Latour, H. J. Vreman, R. J. Wong, D. K. Stevenson, P. Steendijk, J. Egberts, and T. G. Krediet Is carbon monoxide-mediated cyclic guanosine monophosphate production responsible for low blood pressure in neonatal respiratory distress syndrome? J Appl Physiol, March 1, 2005; 98(3): 1044 - 1049. [Abstract] [Full Text] [PDF]

				H. Koelzow, J. A. Gedney, J. Baumann, N. J. Snook, and M. C. Bellamy The Effect of Methylene Blue on the Hemodynamic Changes During Ischemia Reperfusion Injury in Orthotopic Liver Transplantation Anesth. Analg., April 1, 2002; 94(4): 824 - 829. [Abstract] [Full Text] [PDF]

				E. Thorin, P. L. Huang, M. C. Fishman, and J. A. Bevan Nitric Oxide Inhibits {alpha}2-Adrenoceptor–Mediated Endothelium-Dependent Vasodilation Circ. Res., June 29, 1998; 82(12): 1323 - 1329. [Abstract] [Full Text] [PDF]

				B.R. Misra, T.J. Ferranti, L.H. Donnelly, J.E. Erickson, R.G. Schaub, and J.C. Keith Recombinant human interleukin-11 prevents hypotension in LPS-treated anesthetized rabbits Innate Immunity, August 1, 1996; 3(4): 297 - 305. [Abstract] [PDF]

				H. Zhang, P. Rogiers, G. Friedman, J.-C. Preiser, H. Spapen, W. A. Buurman, and J.-L. Vincent Effects of Nitric Oxide Donor SIN-1 on Oxygen Availability and Regional Blood Flow During Endotoxic Shock Arch Surg, July 1, 1996; 131(7): 767 - 774. [Abstract] [PDF]

				A. F. Dominiczak and D. F. Bohr Nitric Oxide and Its Putative Role in Hypertension Hypertension, June 1, 1995; 25(6): 1202 - 1211. [Full Text]